Prescription Required.Why?
A short-acting meglitinide medication that stimulates insulin secretion from the pancreas.
An alpha-glucosidase inhibitor that slows down the breakdown of carbohydrates in the gut, leading to a slower rise in blood sugar levels.
Type 2 diabetes mellitus, when diet and exercise alone are not enough to control blood sugar levels.
Volga R 0.5/0.3 Tab (Repaglinide + Voglibose) works by combining two mechanisms to lower blood sugar levels: Repaglinide stimulates the pancreas to release insulin, and Voglibose slows down the breakdown of carbohydrates in the gut, reducing the absorption of glucose into the bloodstream.
Store the medication in a cool, dry place, protected from light. Keep it out of reach of children.
Dosage should be individualized by your doctor based on your blood sugar levels and response to treatment.
This medication is typically taken before meals, allowing for a more controlled response to food intake.
Follow your doctor's instructions carefully, including the frequency and duration of treatment.
Hypoglycemia (low blood sugar), which may cause symptoms like dizziness, sweating, confusion, and weakness.
Weight gain.
Allergic reactions, which may include rash, itching, or swelling.
Moderate alcohol consumption can increase the risk of hypoglycemia. Consult your doctor about safe alcohol intake.
If you experience hypoglycemia, avoid driving or operating machinery until symptoms subside.
The safety of this medication during pregnancy and breastfeeding has not been established. Consult your doctor before using it.
This medication is not recommended for use in children.
Kidney disease may affect the elimination of this medication. Consult your doctor for appropriate dosage adjustments.
Liver disease may affect the metabolism of this medication. Consult your doctor for appropriate dosage adjustments.
Your doctor or pharmacist.
The medication's package insert.
The website of the US Food and Drug Administration (FDA).
